Format

Send to

Choose Destination
Haematologica. 2019 May 16. pii: haematol.2018.205930. doi: 10.3324/haematol.2018.205930. [Epub ahead of print]

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.

Author information

1
Division of Hematology and Oncology, Innsbruck Medical University, Austria.
2
Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
3
Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milano,Italy.
4
Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
5
Medical Dept. 2, County Hospital, Steyr, Austria.
6
Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Italy.
7
Department of Hematology, Universitaire Ziekenhuizen Leuven, Belgium.
8
Department of Internal Medicine IV, Wels-Grieskirchen Hospital, Wels, Austria.
9
NOXXON Pharma AG, Berlin, Germany.
10
Mologen AG, Berlin, Germany.
11
Hematology and Oncology Department, IRCCS AOU S Martino Hospital, IST, Genova, Italy gobbi@unige.it.

Abstract

Olaptesed pegol (NOX-A12) is a pegylated structured L-oligoribonucleotide that binds and neutralizes CXCL12, a chemokine tightly regulating the life cycle of chronic lymphocytic leukemia cells. The resulting inhibition of CXCR4 and CXCR7 signaling reduces the protective activity of the bone marrow and lymph node microenvironment. CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells to the circulation and prevents their homing into the protective niches. In this phase I/II study, 28 patients with relapsed/refractory chronic lymphocytic leukemia were treated with olaptesed pegol in combination with bendamustine and rituximab. Combination treatment was preceded by single escalating pilot doses of olaptesed pegol in the first 10 patients for evaluation of safety and pharmacokinetics. Peak concentrations and systemic exposure of olaptesed pegol were dose-linear; plasma elimination was monophasic with a 53.2 h half-life. A rapid increase in circulating chronic lymphocytic leukemia cells was observed already 1h after olaptesed pegol administration lasting for at least 72h. Single-agent treatment was well tolerated and no dose-limiting toxicity was observed. The combination regimen yielded an overall response rate of 86%, with 11% of patients achieving a complete response and 75% a partial response. Notably, all 10 high-risk patients including 4 with a 17p deletion responded to treatment. Median progression-free survival was 15.4 (95% CI 12.2, 26.2) months while median overall survival was not reached with > 80% of patients alive after a median follow-up of 28 months. Olaptesed pegol was well tolerated and did not result in additional toxicity when combined with bendamustine and rituximab (NCT01486797). Further clinical development of this novel CXCL12 inhibitor is thus warranted.

KEYWORDS:

Bone Marrow Microenvironment; Chronic Lymphocytic Leukemia; Leukemic Stem Cell; Lymphocytes

PMID:
31097627
DOI:
10.3324/haematol.2018.205930
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center